Charles Schwab Investment Management Inc. Purchases 40,386 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Charles Schwab Investment Management Inc. raised its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 4.2% in the 4th quarter, Holdings Channel reports. The firm owned 996,748 shares of the company’s stock after buying an additional 40,386 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Apellis Pharmaceuticals were worth $31,806,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after acquiring an additional 735,160 shares during the period. Braidwell LP lifted its holdings in shares of Apellis Pharmaceuticals by 410.8% during the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock valued at $90,130,000 after purchasing an additional 2,513,383 shares in the last quarter. Jennison Associates LLC grew its position in shares of Apellis Pharmaceuticals by 51.6% in the 4th quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock valued at $88,084,000 after purchasing an additional 939,289 shares during the period. Geode Capital Management LLC increased its stake in Apellis Pharmaceuticals by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,810,526 shares of the company’s stock worth $52,229,000 after purchasing an additional 22,609 shares in the last quarter. Finally, Barclays PLC raised its holdings in Apellis Pharmaceuticals by 18.0% during the 3rd quarter. Barclays PLC now owns 255,897 shares of the company’s stock worth $7,381,000 after buying an additional 39,019 shares during the period. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 5,569 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares of the company’s stock, valued at approximately $3,482,123. This represents a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO James George Chopas sold 1,096 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $33,351.28. Following the sale, the chief accounting officer now directly owns 48,138 shares in the company, valued at $1,464,839.34. This trade represents a 2.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,934 shares of company stock valued at $1,950,261 over the last three months. 6.80% of the stock is owned by insiders.

Apellis Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ APLS opened at $24.66 on Monday. The stock has a market capitalization of $3.10 billion, a P/E ratio of -12.15 and a beta of 0.92. The stock’s fifty day moving average is $28.33 and its 200 day moving average is $30.50. Apellis Pharmaceuticals, Inc. has a 52 week low of $23.77 and a 52 week high of $59.91. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.73) EPS. Sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on APLS. The Goldman Sachs Group dropped their price objective on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Royal Bank of Canada cut their price target on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Wedbush dropped their target price on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Finally, Morgan Stanley assumed coverage on Apellis Pharmaceuticals in a research report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price target for the company. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $45.53.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).